KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer

被引：0
|
作者：
Cardoso, F. [1 ]
Bardia, A. [2 ]
Andre, F. [3 ]
Cescon, D. W. [4 ]
McArthur, H. [5 ]
Telli, M. [6 ]
Loi, S. [7 ]
Cortes, J. [8 ]
Schmid, P. [9 ]
Harbeck, N. [10 ]
Denkert, C. [11 ]
Jackisch, C. [12 ]
Jia, L. [13 ]
Hirshfield, K. [14 ]
Karantza, V. [15 ]
机构：
[1] Champalimaud Fdn Canc Ctr, Breast Unit, Lisbon, Portugal
[2] Harvard Med Sch, Massachusetts Gen Hosp, Med Oncol, Boston, MA 02115 USA
[3] Gustave Roussy Canc Campus, Med Oncol Dept, Breast Canc Unit, Villejuif, France
[4] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[5] Cedars Sinai Med Ctr, Breast Oncol, Los Angeles, CA 90048 USA
[6] Stanford Univ, Sch Med, Med Med Oncol, Stanford, CA USA
[7] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia
[8] Ramon & Cajal Univ Hosp, Breast Canc Program, Madrid, Spain
[9] Queen Mary Univ London, Barts Canc Inst, Ctr Expt Canc Med, London, England
[10] Ludwig Maximilians Univ Grosshadern, Breast Ctr, Munich, Germany
[11] Uniklinikum Giessen & Marburg, Inst Pathol, Marburg, Germany
[12] Klinikum Offenbach GmbH, Obstet & Gynecol, Offenbach, Germany
[13] Merck & Co Inc, Biostat, Kenilworth, NJ USA
[14] Merck & Co Inc, Oncol Late Stage Dev, Kenilworth, NJ USA
[15] Merck & Co Inc, Clin Res Oncol, Kenilworth, NJ USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24TiP
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
    Favre-Bulle, Andrea
    Huang, Min
    Haiderali, Amin
    Bhadhuri, Arjun
    PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 91 - 101
  • [32] Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
    Schmid, Peter
    Cortes, Javier
    Dent, Rebecca
    Pusztai, Lajos
    McArthur, Heather
    Kuemmel, Sherko
    Denkert, Carsten
    Park, Yeon Hee
    Hui, Rina
    Harbeck, Nadia
    Takahashi, Masato
    Foukakis, Theodoros
    Mouret-Reynier, Marie-Ange
    Ferreira, Marta
    Im, Seock-Ah
    Cardoso, Fatima
    Ding, Yu
    Pan, Wilbur
    Tryfonidis, Konstantinos
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [33] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo -controlled phase 3 study
    Chung, H.
    Bang, Y.
    Fuchs, C.
    Qin, S.
    Satoh, T.
    Shitara, K.
    Tabernero, J.
    Van Cutsem, E.
    Cao, Z.
    Chen, X.
    Kang, S.
    Shih, C.
    Janjigian, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [34] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study
    Chung, Hyun Cheol
    Bang, Yung-Jue
    Fuchs, Charles S.
    Qin, Shukui
    Satoh, Taroh
    Shitara, Kohei
    Tabernero, Josep
    Van Cutsem, Eric
    Alsina, Maria
    Cao, Z. Alexander
    Chen, Xinqun
    Bhagia, Pooja
    Shih, Chie-Schin
    Janjigian, Yelena Yuriy
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [35] Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
    Choueiri, Toni K.
    Tomczak, Piotr
    Park, Se Hoon
    Venugopal, Balaji
    Ferguson, Tom
    Chang, Yen-Hwa
    Hajek, Jaroslav
    Symeonides, Stefan N.
    Lee, Jae-Lyun
    Sarwar, Naveed
    Thiery-Vuillemin, Antoine
    Gross-Goupil, Marine
    Mahave, Mauricio
    Haas, Naomi B.
    Sawrycki, Piotr
    Zhang, Eric
    Rogerio, Jaqueline Willemann
    Imai, Kentaro
    Quinn, David I.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
  • [36] Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial
    Liu, Sai Lan
    Mai, Hai-Qiang
    Wen, Dongxiang
    Yang, Jin-Hao
    Guo, Shan-Shan
    Liu, Li-Ting
    Luo, Mei-Juan
    Liang, YuJing
    Sun, Xue-Song
    Li, Xiao-Yun
    Luo, Dong-Hua
    Li, Ji-Bin
    Wang, Pan
    Guo, Ling
    Mo, Hao-Yuan
    Sun, Rui
    Zhao, Chong
    Xu, Rui-Hua
    Tang, Lin-Quan
    Chen, Qiu-Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.
    Fernando, Hiran C.
    Yang, Jing
    Ferraro, Geri L.
    Keller, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer
    Chavez-MacGregor, Mariana
    Miao, Jieling
    Pusztai, Lajos
    Goetz, Matthew P.
    Rastogi, Priya
    Ganz, Patricia A.
    Mamounas, Eleftherios P.
    Paik, Soonmyung
    Bandos, Hanna
    Razaq, Wajeeha
    O'Dea, Anne
    Kaklamani, Virginia
    Silber, Andrea L. M.
    Flaum, Lisa E.
    Andreopoulou, Eleni
    Wendt, Albert G.
    Carney, Jennifer F.
    Sharma, Priyanka
    Gralow, Julie R.
    Lew, Danika L.
    Barlow, William E.
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (25)
  • [39] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS CHEMOTHERAPY AS NEOADJUVANT THERAPY AND CONTINUED AS A SINGLE AGENT AS ADJUVANT THERAPY FOR HIGH-RISK EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER IN GREECE
    Yfantopoulos, N.
    Athanasopoulos, C.
    Haiderali, A.
    Huang, M.
    Gountas, I
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S91 - S91
  • [40] ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
    Lorusso, D.
    Xiang, Y.
    Colombo, N.
    Coleman, R.
    Randall, L.
    Duska, L.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M. R.
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Marth, C.
    Keefe, S.
    Puglisi, M.
    Pignata, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1341 - S1342
12345